OncoMatch/Pancreatic Cancer (PDAC)/BRCA2
Pancreatic Cancer (PDAC)BRCA2 Clinical Trials
Germline BRCA2 pathogenic variants are the most common hereditary cause of pancreatic cancer (~3–5% of PDAC) and predict sensitivity to platinum-based chemotherapy and PARP inhibition. Olaparib maintenance is FDA-approved for germline BRCA1/2-positive metastatic PDAC with response to first-line platinum. Active trials study PARP inhibitor combinations, somatic BRCA2 eligibility expansion, and neoadjuvant BRCA-targeted strategies.
Top recruiting BRCA2 Pancreatic Cancer (PDAC) trials
Ranked by phase and US site count. See all 4 trials matched to your profile →
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
University Health Network, Toronto
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins